Meta AnalysisID 6101
中成药治疗糖尿病视网膜病变的疗效比较：系统评价与网状Meta分析
CRD42022323996
Which Chinese patent medicine has better clinical effect in treating diabetic retinopathy?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6101
- Evidence Id
- 14659
- Core Evidence Id
- 14659
- Source Meta Analysis Id
- 6083
- Herb2 Meta Analysis Id
- HBMA006083
- Crd Id
- CRD42022323996
- Title
- Comparative effectiveness of Chinese patent medicine for diabetic retinopathy: A systematic review and network meta-analysis
- Review Question
- Which Chinese patent medicine has better clinical effect in treating diabetic retinopathy?
- Study Type Included
- We will include randomized controlled trials to assess the beneficial effects of the treatments.
- Condition Being Studied
- Diabetic retinopathy is a microvascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Currently, vascular endothelial growth factor, laser photocoagulation, and intravitreal steroids are the mainstays for DR treatment, but the efficacy of these treatment strategies remains insufficient. Clinical studies have found that Chinese patent medicine is effective in the treatment of diabetic retinopathy.
- Participant
- Studies were considered eligible for inclusion if the following criteria were met: (1) Randomized controlled trial (RCT) regarding Chinese patent medicine (Compound Danshen Dripping Pills, Qiming Granule, Compound Xueshuantong Capsule) combined with WM (such as calcium dobesilate, anti-hyperglycemia treatment) for the treatment of diabetic retinopathy, regardless of whether blinding methods were used. (2) All included patients were diagnosed with diabetic retinopathy according to specific diagnostic criteria, with no limitations in age, sex, race or disease severity. (3) All patients received treatment with WM. On the basis of this, the experimental group received one of the included Chinese patent medicine, and the control group received another or only WM. Furthermore, if there were complications during the therapeutic process, relevant therapy would be adopted. (4) Outcomes included the vision, macular thickness, plaque area, blood glucose, inflamm atory factor levels and adverse reactions. Studies were excluded if any of the following criteria were met: ① A lack of complete or precise data or the full text was not available. ② For studies with the same data, utilized the data of the study with the larger sample size and more relative complete information. ③ The course of treatment was ambiguous.
- Animal
- Human Disease Modelled
- Intervention
- Chinese patent medicine, including Compound Danshen Dripping Pills, Qiming Granule and Compound Xueshuantong Capsule.
- Comparator Control
- Chinese patent medicine or conventional treatment
- Main Outcome
- The vision, macular thickness, plaque area.
- Outcome Measure
- Additional Outcome
- The blood glucose, inflamm atory factor levels and adverse reactions.
- Study Method
- Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- China; Diabetes Mellitus; Diabetic Retinopathy; Humans; Network Meta-Analysis; Nonprescription Drugs
- Contact
- Xiyuan Deng [email protected]
- Organisational Affiliation
- Graduate School of Chengdu University of traditional Chinese Medicine
- Funding Source
- National Natural Science Foundation of China (81674031), Science and Technology Department of Sichuan Province (2021YJ0252), Research Fund of Chengdu University of traditional Chinese Medicine XSGG2020003
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-04-09
- Registration Date
- 2022-05-09
- Anticipated Start Date
- 2022-04-09
- Anticipated Completion Date
- 2022-05-08
- Title Cn
- 中成药治疗糖尿病视网膜病变的疗效比较：系统评价与网状Meta分析
- Title En
- Comparative effectiveness of Chinese patent medicine for diabetic retinopathy: A systematic review and network meta-analysis
- Bilingual Status
- complete